Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS)

NCT03047395 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03047395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03047395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS)
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
February 27, 2017
Completion date
November 29, 2023
Enrollment
2,170 (actual)
Sites
233

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis